United States Medical Device Regime Compared with Ten Other Markets

1. Key takeaways

The differences between the United States medical device regime and the ten other markets covered here concentrate on four points: the classification system (the United States uses Class I/II/III), the role of the local entity (the United States uses a US Agent plus an initial importer, while most of the other markets use a license holder or authorized representative), the form of certificate validity (the United States has no product registration certificate, and establishment registration must be renewed annually by fiscal year), and the vigilance deadlines (the United States works on the calendar-day and working-day matrix of 21 CFR 803). These four dimensions are the ones where a company moving between the United States and the other markets is most likely to carry over assumptions from one system that do not hold in the other.

2. Legal basis

The United States provisions cited in this comparison are the following, in force as of the verification date noted at the end of this page.

Comparison table for the eleven markets (practical estimate, each market governed by its local regulations):

3. Expert insights

Insight one: the local entity in the United States is a dual role, and the scope of responsibility is the narrowest.

The United States uses two roles, the US Agent plus the initial importer. According to the official FDA page, the US Agent does not bear MDR and 510(k) submission obligations, so the scope of responsibility is clearly narrower than what most markets demand of a license holder or authorized representative. Companies accustomed to markets where the local entity is accountable for the filing itself should not assume the US Agent plays the same part; the practical estimate is that the US Agent functions as a communication and designation point, while the substantive obligations remain with the manufacturer and the importer.

Insight two: the United States has no document in the form of a product registration certificate.

In the table above, markets such as Thailand, the Philippines, India, Bangladesh, Pakistan, and Sri Lanka all have registration certificates with validity periods. The United States instead has a trio of establishment registration (renewed by fiscal year), device listing, and a premarket clearance or approval letter. This is the cognitive shift companies from China and elsewhere most need to make when running a United States project: the deliverable set is different, and requesting a certificate that does not exist creates confusion in contracts, audits, and customer due diligence.

Insight three: vigilance deadlines show the widest divergence in calculation conventions and must be recorded separately for each market.

The United States uses a dual convention of calendar days and working days (30 calendar days, 5 working days, 10 working days); Thailand uses 48 hours, 10 calendar days, and 30 days; Singapore uses 48 hours, 10 calendar days, and 30 calendar days; Bangladesh uses 10 working days for serious events. What is nominally ten days differs in actual elapsed time across the three conventions of calendar days, working days, and natural days. A single global vigilance deadline in a procedure document is therefore misleading, pending verification of each market’s current rule.

Insight four: the United States annual update window overlaps with that of some other markets.

The United States annual registration update runs from October 1 to December 31, and this window overlaps with the annual update periods of some other markets. A multinational company can use one concentrated window to handle annual affairs across several markets, but the specific actions in each market differ and cannot be merged into a single execution. Scheduling can be centralized; execution cannot.

4. Practical recommendations

• Build a four-column table for each market covering classification, local entity, validity, and vigilance deadlines, without merging markets.
• Calculate vigilance deadlines separately for natural days, calendar days, and working days, and produce a side-by-side comparison.
• For United States projects, do not presuppose a registration certificate as the deliverable; instead deliver the trio of registration number, listing number, and clearance or approval letter.
• For markets whose annual update windows overlap, keep the actions separate but schedule them in one concentrated period.
• Include a cross-market role-name comparison table in staff training to prevent terminology mixing.

5. Verification checklist

• □ A four-column comparison table has been built for each market
• □ Vigilance deadlines have been calculated separately for natural days, calendar days, and working days
• □ The deliverables list for United States projects has been changed to the trio
• □ Annual update windows have been set separately for each market
• □ The cross-market role-name comparison table has been included in training
• □ The comparison tables are marked as practical estimate, each market governed by its local regulations

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com